Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene

被引:64
作者
Chen, Ji-Long [1 ]
Limnander, Andre [1 ]
Rothman, Paul B. [1 ]
机构
[1] Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Internal Med, Iowa City, IA 52242 USA
关键词
D O I
10.1182/blood-2007-04-083808
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The precise mechanisms by which AN oncogenes transform hernatopoietic cells are unknown. We have examined the role of Pim kinases in v-AbI-mediated transformation. In v-AbI transformants, expression of Pim-1 and Pim-2, but not Pim-3, is dependent on AbI kinase activity. Transformation assays demonstrate that v-AbI cannot efficiently transform bone marrow cells derived from Pim-1(-/-)/Pim-2(-/-) mice. Ectopic expression of either Pim-1 or Pim-2 in Pim-1(-/-)/Pim-2(-/-) cells restores transformation by v-AbI, strongly suggesting that either Pim-1 or Pim-2 is required for v-AbI-mediated tumorigenesis. Interestingly, the combined deficiency of Pim-1, Pim-2, and Suppressor of Cytokine Signalling (SOCS)-1 resulted in partial restoration of v-AbI transformation efficiency. In addition, Pim kinases are involved in modification of SOCS-1 and in regulating SOCS-1 protein levels in v-AbI-transformed cells. Furthermore, Pim kinases regulate the proapoptotic proteins Bcl-XS and BAD. Pim kinases inhibit the expression of Bcl-XS. Pim deficiency decreases the phosphorylation levels of BAD, whereas ectopic expression of Pim-1 increases the amount of phospho-BAD. This correlates with an increased protection from apoptosis in AbI transformants expressing Pim kinases. Together, these data suggest that Pim kinases play a key role in the v-AbI transformation, possibly via participating in modulation of SOCS-1 and via regulating the apoptotic signaling.
引用
收藏
页码:1677 / 1685
页数:9
相关论文
共 40 条
[1]   Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL [J].
Adam, M ;
Pogacic, V ;
Bendit, M ;
Chappuis, R ;
Nawijn, MC ;
Duyster, J ;
Fox, CJ ;
Thompson, CB ;
Cools, J ;
Schwaller, J .
CANCER RESEARCH, 2006, 66 (07) :3828-3835
[2]   Pim-1 kinase promotes inactivation of the pro-apoptotic bad protein by phosphorylating it on the Ser112 gatekeeper site [J].
Aho, TLT ;
Sandholm, J ;
Peltola, KJ ;
Mankonen, HP ;
Lilly, M ;
Koskinen, PJ .
FEBS LETTERS, 2004, 571 (1-3) :43-49
[3]   Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc [J].
Allen, JD ;
Verhoeven, E ;
Domen, J ;
vanderValk, M ;
Berns, A .
ONCOGENE, 1997, 15 (10) :1133-1141
[4]   The survival kinases Akt and Pim as potential pharmacological targets [J].
Amaravadi, R ;
Thompson, CB .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (10) :2618-2624
[5]   THE HUMAN PROTOONCOGENE PRODUCT P33PIM IS EXPRESSED DURING FETAL HEMATOPOIESIS AND IN DIVERSE LEUKEMIAS [J].
AMSON, R ;
SIGAUX, F ;
PRZEDBORSKI, S ;
FLANDRIN, G ;
GIVOL, D ;
TELERMAN, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (22) :8857-8861
[6]   The serine/threonine kinase pim-1 [J].
Bachmann, M ;
Möröy, T .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2005, 37 (04) :726-730
[7]  
Banerjee A, 1998, J IMMUNOL, V161, P4611
[8]   BCL-X, A BCL-2-RELATED GENE THAT FUNCTIONS AS A DOMINANT REGULATOR OF APOPTOTIC CELL-DEATH [J].
BOISE, LH ;
GONZALEZGARCIA, M ;
POSTEMA, CE ;
DING, LY ;
LINDSTEN, T ;
TURKA, LA ;
MAO, XH ;
NUNEZ, G ;
THOMPSON, CB .
CELL, 1993, 74 (04) :597-608
[9]   Pim serine/threonine kinases regulate the stability of Socs-1 protein [J].
Chen, XP ;
Losman, JA ;
Cowan, S ;
Donahue, E ;
Fay, S ;
Vuong, BQ ;
Nawijn, MC ;
Capece, D ;
Cohan, VL ;
Rothman, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (04) :2175-2180
[10]   Up-regulation of a serine-threonine kinase protooncogene Pim-1 in oral squamous cell carcinoma [J].
Chiang, W. -F. ;
Yen, C. -Y. ;
Lin, C. -N. ;
Liaw, G. -A. ;
Chiu, C. -T. ;
Hsia, Y. -J. ;
Liu, S. -Y. .
INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2006, 35 (08) :740-745